靶向TIM-3治疗血液系统恶性肿瘤：2022年美国血液学会年会的最新进展
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting.
作者信息
Tan Jiaxiong, Tan Huo, Li Yangqiu
机构信息
Department of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou, China.
Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, 510632, Guangzhou, China.
出版信息
Exp Hematol Oncol. 2023 Jul 19;12(1):62. doi: 10.1186/s40164-023-00421-2.
Abstract
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022).
摘要
T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）是癌症免疫抑制中一种重要的免疫检查点（IC）蛋白，被认为是免疫治疗的新靶点。此外，TIM-3作为一种免疫髓系调节因子，在几种实体瘤细胞和髓系白血病干细胞（LSCs）上高度表达。TIM-3阻断已显示出直接抑制白血病细胞和恢复T细胞活化的双重作用。我们总结了2022年美国血液学会年会（ASH2022）上关于TIM-3在血液系统恶性肿瘤免疫治疗中作用的几篇最新报道。
相似文献
1
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting.靶向TIM-3治疗血液系统恶性肿瘤：2022年美国血液学会年会的最新进展
Exp Hematol Oncol. 2023 Jul 19;12(1):62. doi: 10.1186/s40164-023-00421-2.
2
TIM-3 in Leukemia; Immune Response and Beyond.白血病中的TIM-3；免疫反应及其他
Front Oncol. 2021 Sep 30;11:753677. doi: 10.3389/fonc.2021.753677. eCollection 2021.
3
TIM-3 pathway dysregulation and targeting in cancer.癌症中TIM-3通路的失调与靶向治疗
Expert Rev Anticancer Ther. 2021 May;21(5):523-534. doi: 10.1080/14737140.2021.1865814. Epub 2021 Jan 19.
4
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.血液系统恶性肿瘤的新型细胞免疫疗法：2021年美国血液学会年会的最新进展
Exp Hematol Oncol. 2022 Sep 24;11(1):61. doi: 10.1186/s40164-022-00316-8.
5
Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?用α-乳糖调节Gal-9/TIM-3免疫检查点。乳糖的异头物重要吗？
Cancers (Basel). 2021 Dec 18;13(24):6365. doi: 10.3390/cancers13246365.
6
[TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in human acute myeloid leukemia].[TIM-3信号传导劫持经典Wnt/β-连环蛋白通路以维持人类急性髓系白血病中的癌症干细胞特性]
Rinsho Ketsueki. 2023;64(6):547-552. doi: 10.11406/rinketsu.64.547.
7
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.用于血液系统恶性肿瘤的双靶点嵌合抗原受体T细胞免疫疗法：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Feb 27;13(1):25. doi: 10.1186/s40164-024-00485-8.
8
TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.TIM-3 在正常和恶性造血中的作用：结构、功能和信号通路。
Cancer Sci. 2021 Sep;112(9):3419-3426. doi: 10.1111/cas.15042. Epub 2021 Jul 14.
9
Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.联合免疫检查点阻断增强了抗病毒免疫对牛白血病病毒。
J Virol. 2023 Jan 31;97(1):e0143022. doi: 10.1128/jvi.01430-22. Epub 2023 Jan 4.
10
C-5401331 identified as a novel T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) inhibitor to control acute myeloid leukemia (AML) cell proliferation.C-5401331 被鉴定为一种新型 T 细胞免疫球蛋白和粘蛋白结构域蛋白 3（Tim-3）抑制剂，可控制急性髓细胞白血病（AML）细胞增殖。
Med Oncol. 2024 Jan 24;41(3):63. doi: 10.1007/s12032-023-02296-z.
引用本文的文献
1
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy.TIM3的表面下调可保护健康细胞，但不能保护急性髓性白血病免受CAR T细胞疗法的影响。
Hemasphere. 2025 Jul 13;9(7):e70155. doi: 10.1002/hem3.70155. eCollection 2025 Jul.
2
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.利用肿瘤微环境：通过调节上皮-间质转化实现靶向癌症治疗
J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6.
3
Myofibroblasts persist through immune privilege mechanisms to mediate oral submucous fibrosis: Uncovering the pathogenesis.肌成纤维细胞通过免疫豁免机制持续存在，介导口腔黏膜下纤维化：揭示发病机制。
J Oral Biol Craniofac Res. 2024 Nov-Dec;14(6):773-781. doi: 10.1016/j.jobcr.2024.10.008. Epub 2024 Oct 20.
4
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.多发性骨髓瘤与新型免疫检查点抑制剂的免疫治疗潜力
Ther Adv Vaccines Immunother. 2024 Oct 9;12:25151355241288453. doi: 10.1177/25151355241288453. eCollection 2024.
5
Higher frequency of peripheral blood CD103CD8 T cells with lower levels of PD-1 and TIGIT expression related to favorable outcomes in leukemia patients.外周血 CD103CD8 T 细胞表达 PD-1 和 TIGIT 水平较低与白血病患者的良好预后相关。
Front Immunol. 2024 Sep 25;15:1437726. doi: 10.3389/fimmu.2024.1437726. eCollection 2024.
6
Breaking Boundaries: Immunotherapy for Myeloid Malignancies.突破界限：髓系恶性肿瘤的免疫疗法
Cancers (Basel). 2024 Aug 6;16(16):2780. doi: 10.3390/cancers16162780.
7
To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.通过分析免疫微环境，开发用于预测食管鳞癌新辅助免疫化疗疗效的预后模型。
Front Immunol. 2024 Apr 25;15:1312380. doi: 10.3389/fimmu.2024.1312380. eCollection 2024.
8
Higher TIGIT+ γδ T cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML.高表达 TIGIT+γδ T 细胞可能预示着年轻成人非急性早幼粒细胞白血病患者预后不良。
Front Immunol. 2024 Apr 22;15:1321126. doi: 10.3389/fimmu.2024.1321126. eCollection 2024.
本文引用的文献
1
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?多发性骨髓瘤中 CAR T 或 BiTE 治疗的患者选择：每位患者的哪种治疗方法？
J Hematol Oncol. 2022 Jun 7;15(1):78. doi: 10.1186/s13045-022-01296-2.
2
Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function.设计和评估 TIM-3-CD28 检查点融合蛋白以改善抗 CD19 CAR T 细胞功能。
Front Immunol. 2022 Apr 6;13:845499. doi: 10.3389/fimmu.2022.845499. eCollection 2022.
3
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.TIM-3 是一个有前途的靶点，可以选择性地杀死急性髓系白血病干细胞。
Cell Stem Cell. 2010 Dec 3;7(6):708-17. doi: 10.1016/j.stem.2010.11.014.
Zotero 插件